Chidamide, a novel histone deacetylase inhibitor, suppresses myeloma proliferation via inhibiting proteasome activity and ASH2L gene expression
The impact of epigenetic regulations on myeloma cells is attracting more and more attention. Chidamide, a novel histone deacetylase inhibitor (HDACi) independently developed in China, has been approved for the treatment of T cell lymphoma. Yet its action on myeloma is not elucidated. We previously found that ASH2L gene, which enhanced the activity of oncogene methyltransferase, was highly expressed in some patients with multiple myeloma (MM). The main purpose of this study is to investigate the anti-myeloma effects of Chidamide and ASH2L involvement.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Yunyan Zan, Duoduo Zhao, Jingting Zhao, Junling Zhuang Source Type: research
More News: China Health | Genetics | Hematology | Leukemia | Lymphoma | Myeloma | Study | T-cell Lymphoma